From Compliance to Control: Bridging EU Regulation, US Innovation, & Next-Generation Omega-3 Strategies
- Compare EU and US regulatory philosophies shaping infant lipid strategies: Explore the strengths and limitations of prescriptive versus innovation-driven approaches through examples such as mandatory DHA, MOSH/MOAH, PFAS, and their impact on DHA sourcing and formulation choices
- Translate market and scientific realities into infant lipid design: Leverage market insights to compare DHA and ARA usage, sourcing strategies, and the slower transition toward algal solutions in Europe, while reviewing the latest evidence on DHA/ARA balance and ongoing scientific debate
- Enable next-generation lipid systems through precision fermentation: Discuss how advances in sourcing and fermentation technologies enable higher purity, traceability, consistency, and resilience, opening the path toward more complete and future-ready lipid systems beyond traditional omega 3